Nathalie Asherie

Hebrew University of Jerusalem — Israel

Biochemistry, Genetics and Molecular Biology · Life Sciences

10h-index264citations35works6.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Amyloidosis: Diagnosis, Treatment, Outcomes(14), Multiple Myeloma Research and Treatments(12), CAR-T cell therapy research(12), Chronic Myeloid Leukemia Treatments(7), Parathyroid Disorders and Treatments(6)

Publications35 total

Supplementary Table 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Supplementary Figures S1-S7 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Supplementary Data 1 from Feasibility of a Novel Academic BCMA-CART (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
2025Open Access
Prospective predictors of toxicity of BCMA‑directed CART therapy in multiple myeloma
Blood·2025
Summary analysis of the phase 1a/b study with HBI0101, an academic anti-BCMA chimeric antigen receptor T-cell (CART) for relapsed/refractory multiple myeloma
Blood·2025Open Access
BCMA-targeted CAR T-cell therapy in refractory autoimmune diseases: Initial Results from a Phase 1 clinical trial
Blood·2025Open Access
High Rate of Cytokine Release Syndrome-Related Coagulopathy with Low Incidence of Bleeding and Thrombosis in Patients Treated with B-Cell Maturation Antigen (BCMA)-Targeted Chimeric Antigen Receptor T-Cells (CAR-T)
Cancers·2025· 1 citedOpen Access
Efficacy and Safety of Anti–B-Cell Maturation Antigen Chimeric Antigen Receptor T-Cell for the Treatment of Relapsed and Refractory AL Amyloidosis
Journal of Clinical Oncology·2024· 14 cited
Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis
Blood·2024· 2 citedOpen Access
Efficacy of HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
Blood·2024· 3 citedOpen Access
OA-34 HBI0101, an Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for Relapsed/Refractory Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2024
P-023 Efficacy and Safety of CAR T-cell Therapy for Plasma Cell Leukemia
Clinical Lymphoma Myeloma & Leukemia·2024
Clinical evaluation and determinants of response to HBI0101 (BCMA CART) therapy in relapsed/refractory multiple myeloma
Blood Advances·2024· 10 citedOpen Access
Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis PA142 (#103)
2024· 3 cited
Development and Validation of a Prediction Model of Outcome After B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Journal of Clinical Oncology·2024· 70 citedOpen Access
Feasibility of a Novel Academic Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory AL Amyloidosis
Blood·2023· 9 cited
Towards a Decision Engine for Therapeutic Optimization of Relapsed Refractory Multiple Myeloma
Blood·2023
Safety and Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101) for the Treatment of Relapsed and Refractory Multiple Myeloma
Blood·2023· 1 citedOpen Access
P-026 Safety and efficacy of a locally produced novel anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory multiple myeloma
Clinical Lymphoma Myeloma & Leukemia·2023
OA-34 Feasibility of a novel academic anti-BCMA chimeric antigen receptor T-cell (CART) (HBI0101) for the treatment of relapsed and refractory AL amyloidosis
Clinical Lymphoma Myeloma & Leukemia·2023· 1 cited
page 1 of 2Next →

Frequent Co-authors

Polina Stepensky(35), Miri Assayag(32), Shlomit Kfir‐Erenfeld(31), Sigal Grisariu(29), Batia Avni(29), Eyal Lebel(29), Moshe E. Gatt(29), Eran Zimran(28), Cyrille J. Cohen(25), Marjorie Pick(24), Yaël C. Cohen(24), Irit Avivi(19), Adir Shaulov(17), Tatyana Dubnikov Sharon(14), Shlomo Elias(14), Nomi Zalcman(7), Tatyana Dubnikov(6), Vladimir Vainstein(5), Alaa Shehadeh(5), Aseel Ishtay(5)